Genome-wide association studies (GWAS) show that many common alleles confer risk for developing Alzheimer's disease (AD). These risk loci may contribute to MRI alterations in young individuals, preceding the clinical manifestations of AD. Prior evidence identifies vascular dysregulation as the earliest marker of disease progression. However, it remains unclear whether cerebrovascular function (measured via grey-matter cerebral blood flow (gmCBF)) is altered in young individuals with increased AD genetic risk. We establish relationships between gmCBF with APOE and AD polygenic risk score in a young cohort (N = 75; aged: 19-32). Genetic risk was assessed via a) possessing at least one copy of the APOE ɛ4 allele and b) a polygenic risk score (...
Objective: To examine associations between aggregate genetic risk and Alzheimer disease (AD) markers...
Drugs developed to slow, halt or reverse the progression of Alzheimer’s Disease (AD) have failed to ...
Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) pr...
Genome-wide association studies (GWAS) show that many common alleles confer risk for developing Alzh...
Cerebrovascular dysregulation is a hallmark feature of Alzheimer’s disease (AD), where alterations i...
Cerebrovascular dysregulation such as altered cerebral blood flow (CBF) can be observed in Alzheimer...
Background Recent genome-wide association studies have identified genetic loci that jointly make a c...
AbstractBackgroundRecent genome-wide association studies have identified genetic loci that jointly m...
Preclinical models of Alzheimer’s disease (AD) suggest APOE modulates brain function in structures v...
The human apolipoprotein E (APOE) gene has three alleles (ε2, ε3 and ε4). Re...
The human apolipoprotein E (APOE) gene has three alleles (ε2, ε3 and ε4). Relative to the most commo...
Aging-related cognitive decline can be accelerated by a combination of genetic factors, cardiovascul...
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects older people. It...
Whether novel risk variants of Alzheimer's disease (AD) identified through genome-wide association s...
Objective: To examine associations between aggregate genetic risk and Alzheimer disease (AD) markers...
Drugs developed to slow, halt or reverse the progression of Alzheimer’s Disease (AD) have failed to ...
Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) pr...
Genome-wide association studies (GWAS) show that many common alleles confer risk for developing Alzh...
Cerebrovascular dysregulation is a hallmark feature of Alzheimer’s disease (AD), where alterations i...
Cerebrovascular dysregulation such as altered cerebral blood flow (CBF) can be observed in Alzheimer...
Background Recent genome-wide association studies have identified genetic loci that jointly make a c...
AbstractBackgroundRecent genome-wide association studies have identified genetic loci that jointly m...
Preclinical models of Alzheimer’s disease (AD) suggest APOE modulates brain function in structures v...
The human apolipoprotein E (APOE) gene has three alleles (ε2, ε3 and ε4). Re...
The human apolipoprotein E (APOE) gene has three alleles (ε2, ε3 and ε4). Relative to the most commo...
Aging-related cognitive decline can be accelerated by a combination of genetic factors, cardiovascul...
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects older people. It...
Whether novel risk variants of Alzheimer's disease (AD) identified through genome-wide association s...
Objective: To examine associations between aggregate genetic risk and Alzheimer disease (AD) markers...
Drugs developed to slow, halt or reverse the progression of Alzheimer’s Disease (AD) have failed to ...
Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) pr...